The rationale for developing HDACi as anticancer agents was

2022-01-03

The rationale for developing HDACi as anticancer agents was based on their ability to induce the hyperacetylation of histones and nonhistone proteins, resulting in increased differentiation, apoptosis, and Embelin synthesis arrest of cancer cells 1, 2, 3. HDACi have been used in the treatment of he